FDA analysis indicates second J&J shot provides greater immunity than first

Food and Drug Administration staff provided their analysis of Johnson & Johnson’s COVID-19 booster application today, indicating that a second dose provides substantially more protection against SARS-CoV-2 than the initial shot. The analysis is among a trove of data that will be considered this week by the agency’s Vaccines and Related Biological Products Advisory Committee. According to FDA’s analysis, a second, booster dose of the J&J vaccine yielded a 94% efficacy against moderate-to-severe COVID-19; data indicates that the first dose’s efficacy is 70%.